Canaccord Genuity reiterated a Buy rating on Aerie Pharma (NASDAQ: AERI), and raised the price target to $44.00 (from $40.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst PT Change

Pre-Open Stock Movers 09/17: (AERI) (CVC) (LAKE) Higher; (APOG) (TEX) (RAD) Lower (more...)September 17, 2015 9:27 AM RBC Capital Boosts PT on Aeri Pharma (AERI) to $44 Following Rhopressa Phase 3 DataSeptember 17, 2015 9:00 AM Aerie Pharma (AERI) PT Raised to $40 at Cantor FitzgeraldSeptember 17, 2015 7:24 AM Aerie Pharma (AERI) PT Raised to $48 at Brean CapitalSeptember 17, 2015 6:59 AM Aerie Pharma (AERI) PT Raised to $45 at Needham & CompanySeptember 17, 2015 6:22 AM After Hours Stocks Movers 09/16: (AERI) (LAKE) (MLHR) Higher; (APOG) (SANW) (ORCL) Lower (more...)September 16, 2015 5:47 PM Market Wrap: CPI Falls for First Time in Months on Lower Oil; Big Beer Deal in the Works; FedEx Hit on Lowered OutlookSeptember 16, 2015 5:29 PM Aerie Pharma (AERI) Announces Rhopressa Phase 3 Met Primary Efficacy EndpointSeptember 16, 2015 4:04 PM Aerie Pharmaceuticals Reports Positive Rhopressa™ Phase 3 Efficacy ResultsSeptember 16, 2015 4:01 PM